RPSM
CYTK icon

Royalty Pharma Sub-Manager’s Cytokinetics CYTK Stock Holding History

Royalty Pharma Sub-Manager’s Portfolio CYTK Stock Details CYTK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$83.5M Hold
980,392
– – 34.52% 1
2026
Q1 		$64.6M Hold
980,392
– – 37.4% 1
2025
Q4 		$62.3M Buy
+980,392
New +$61M 36.36% 1

Other funds holding CYTK

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Royalty Pharma Sub-Manager's CYTK Position: Q2 2026 in Review

Royalty Pharma Sub-Manager held its Cytokinetics (CYTK) position steady in Q2 2026 at 980,392 shares worth $83.5M. The position accounts for 34.52% of the portfolio, ranked #1.

Royalty Pharma Sub-Manager first reported a position in CYTK in Q4 2025 and has held it in 3 quarters since. 480 funds tracked by Wall St. Rank hold CYTK as of Q2 2026.

  • Royalty Pharma Sub-Manager held 980,392 shares of Cytokinetics worth $83.5M as of Q2 2026.
  • Royalty Pharma Sub-Manager left its Cytokinetics share count unchanged in Q2 2026.
  • Cytokinetics made up 34.52% of Royalty Pharma Sub-Manager's portfolio in Q2 2026, its #1 holding.
  • Royalty Pharma Sub-Manager first reported a position in Cytokinetics in Q4 2025 and has held it in 3 quarters since.
  • 480 funds tracked by Wall St. Rank held Cytokinetics as of Q2 2026.

Based on Royalty Pharma Sub-Manager's 13F filing for Q2 2026, filed 14 Aug 2026.